

Jesper Eugen-Olsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4612392/publications.pdf>

Version: 2024-02-01

98
papers

4,185
citations

136740

32
h-index

128067

60
g-index

105
all docs

105
docs citations

105
times ranked

4907
citing authors

#	ARTICLE	IF	CITATIONS
1	Elevated preoperative suPAR is a strong and independent risk marker for postoperative complications in patients undergoing major noncardiac surgery (SPARSE). <i>Surgery</i> , 2022, 171, 1619-1625.	1.0	9
2	ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically Ill COVID-19 Patients. <i>Journal of Innate Immunity</i> , 2022, 14, 218-228.	1.8	21
3	Chronic inflammation markers and cytokine-specific autoantibodies in Danish blood donors with restless legs syndrome. <i>Scientific Reports</i> , 2022, 12, 1672.	1.6	6
4	Soluble urokinase plasminogen activator receptor and functionally relevant coronary artery disease: a prospective cohort study. <i>Biomarkers</i> , 2022, 27, 278-285.	0.9	2
5	Soluble urokinase plasminogen activator receptor and decline in kidney function among patients without kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1534-1541.	1.4	2
6	Soluble Urokinase Receptor Levels Are Not Affected by the Systemic Inflammatory Response to Anesthesia and Operative Trauma. <i>European Surgical Research</i> , 2022, 63, 249-256.	0.6	3
7	Circulating suPAR associates with severity and in-hospital progression of COVID-19. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13794.	1.7	10
8	Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor. <i>Frontiers in Pharmacology</i> , 2022, 13, 799915.	1.6	3
9	IL-1 Mediates Tissue-Specific Inflammation and Severe Respiratory Failure in COVID-19. <i>Journal of Innate Immunity</i> , 2022, 14, 643-656.	1.8	18
10	Association of Preoperative Basal Inflammatory State, Measured by Plasma suPAR Levels, with Intraoperative Sublingual Microvascular Perfusion in Patients Undergoing Major Non-Cardiac Surgery. <i>Journal of Clinical Medicine</i> , 2022, 11, 3326.	1.0	4
11	Association Between Elevated suPAR, a New Biomarker of Inflammation, and Accelerated Aging. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 318-327.	1.7	34
12	suPAR Cut-Offs for Risk Stratification in Patients With Symptoms of COVID-19. <i>Biomarker Insights</i> , 2021, 16, 117727192110346.	1.0	15
13	Evaluation of commercially available immuno-magnetic agglutination in comparison to enzyme-linked immunosorbent assays for rapid point-of-care diagnostics of COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 3084-3091.	2.5	7
14	Soluble Urokinase Plasminogen Activator Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in the Emergency Department. <i>Journal of Emergency Medicine</i> , 2021, 61, 298-313.	0.3	16
15	An open label trial of anakinra to prevent respiratory failure in COVID-19. <i>ELife</i> , 2021, 10, .	2.8	127
16	FC 043 SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR (SUPAR) DETERMINES OUTCOMES IN CLINICAL AND EXPERIMENTAL SEPTIC ACUTE KIDNEY INJURY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
17	Leukocyte Activation Profile Assessed by Raman Spectroscopy Helps Diagnosing Infection and Sepsis. , 2021, 3, e0394.		17
18	Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor. <i>Communications Biology</i> , 2021, 4, 655.	2.0	12

#	ARTICLE	IF	CITATIONS
19	Circulating Osteopontin Levels and Outcomes in Patients Hospitalized for COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 3907.	1.0	17
20	Using soluble urokinase plasminogen activator receptor to stratify patients for medication review in the emergency department. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	3
21	Utility of suPAR and NGAL for AKI Risk Stratification and Early Optimization of Renal Risk Medications among Older Patients in the Emergency Department. <i>Pharmaceuticals</i> , 2021, 14, 843.	1.7	13
22	Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. <i>Nature Medicine</i> , 2021, 27, 1752-1760.	15.2	353
23	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. <i>Lancet Rheumatology</i> , The, 2021, 3, e690-e697.	2.2	121
24	Linking stressful life events and chronic inflammation using suPAR (soluble urokinase plasminogen) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.0	22
25	Sinus bradycardia is associated with poor outcome in critically ill patients with COVID-19 due to the B.1.1.7 Lineage. <i>Toxicology Reports</i> , 2021, 8, 1394-1398.	1.6	6
26	Investigating the inflammation marker neutrophil-to-lymphocyte ratio in Danish blood donors with restless legs syndrome. <i>PLoS ONE</i> , 2021, 16, e0259681.	1.1	2
27	Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 780641.	2.2	61
28	Angiotensinâ€‘Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVIDâ€‘19. <i>Journal of the American Heart Association</i> , 2021, 10, e023535.	1.6	15
29	Association of Adverse Experiences and Exposure to Violence in Childhood and Adolescence With Inflammatory Burden in Young People. <i>JAMA Pediatrics</i> , 2020, 174, 38.	3.3	80
30	Abnormal routine blood tests as predictors of mortality in acutely admitted patients. <i>Clinical Biochemistry</i> , 2020, 77, 14-19.	0.8	2
31	Soluble Urokinase Receptor (SuPAR) in COVID-19â€‘Related AKI. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2725-2735.	3.0	93
32	SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease. <i>Scandinavian Cardiovascular Journal</i> , 2020, 54, 339-345.	0.4	11
33	Elevated suPAR Is an Independent Risk Marker for Incident Kidney Disease in Acute Medical Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 339.	1.8	15
34	Soluble urokinase plasminogen activator receptor (suPAR) is lower in disease-free patients but cannot rule out incident disease in patients with suspected cancer. <i>Clinical Biochemistry</i> , 2020, 84, 31-37.	0.8	5
35	Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. <i>Critical Care</i> , 2020, 24, 187.	2.5	140
36	Soluble urokinase receptor as a predictor of non-cardiac mortality in patients with percutaneous coronary intervention treated ST-segment elevation myocardial infarction. <i>Clinical Biochemistry</i> , 2020, 80, 8-13.	0.8	1

#	ARTICLE	IF	CITATIONS
37	<p>High suPAR and Low Blood Eosinophil Count are Risk Factors for Hospital Readmission and Mortality in Patients with COPD</p>. International Journal of COPD, 2020, Volume 15, 733-743.	0.9	13
38	Cumulative childhood risk is associated with a new measure of chronic inflammation in adulthood. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2019, 60, 199-208.	3.1	64
39	Effects of 1Âyear of exercise training versus combined exercise training and weight loss on body composition, low-grade inflammation and lipids in overweight patients with coronary artery disease: a randomized trial. Cardiovascular Diabetology, 2019, 18, 127.	2.7	59
40	Soluble urokinase plasminogen activator receptor is linearly associated with dietary quality and predicts mortality. British Journal of Nutrition, 2019, 121, 699-708.	1.2	5
41	Healthy lifestyles reduce suPAR and mortality in aDanish general population study. Immunity and Ageing, 2019, 16, 1.	1.8	59
42	Early Discharge from the Emergency Department Based on Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels: A TRIAGE III Substudy. Disease Markers, 2019, 2019, 1-8.	0.6	19
43	Risk assessment models for potential use in the emergency department have lower predictive ability in older patients compared to the middle-aged for short-term mortality â€“ a retrospective cohort study. BMC Geriatrics, 2019, 19, 134.	1.1	11
44	Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes. Diabetes Care, 2019, 42, 1112-1119.	4.3	38
45	Availability of suPAR in emergency departments may improve risk stratification: a secondary analysis of the TRIAGE III trial. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2019, 27, 43.	1.1	15
46	The biomarkers suPAR and blood eosinophils are associated with hospital readmissions and mortality in asthma â€“ a retrospective cohort study. Respiratory Research, 2019, 20, 258.	1.4	12
47	Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments. World Journal of Surgery, 2019, 43, 780-790.	0.8	6
48	Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapyâ€“mediated Viral Suppression. Clinical Infectious Diseases, 2019, 69, 676-686.	2.9	49
49	Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency. Endocrine Connections, 2019, 8, 772-779.	0.8	3
50	SuPAR predicts postoperative complications and mortality in patients with asymptomatic aortic stenosis. Open Heart, 2018, 5, e000743.	0.9	11
51	suPAR is associated with risk of future acute surgery and post-operative mortality in acutely admitted medical patients. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2018, 26, 11.	1.1	14
52	Effect of simvastatin and ezetimibe on suPAR levels and outcomes. Atherosclerosis, 2018, 272, 129-136.	0.4	6
53	Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study*. Critical Care Medicine, 2018, 46, 1961-1968.	0.4	53
54	Use of the prognostic biomarker suPAR in the emergency department improves risk stratification but has no effect on mortality: a cluster-randomized clinical trial (TRIAGE III). Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2018, 26, 69.	1.1	25

#	ARTICLE	IF	CITATIONS
55	Histological and Molecular Adipose Tissue Changes Are Related to Metabolic Syndrome Rather Than Lipodystrophy in Human Immunodeficiency Virus-Infected Patients: A Cross-Sectional Study. <i>Journal of Infectious Diseases</i> , 2018, 218, 1090-1098.	1.9	4
56	Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD. <i>Respiratory Research</i> , 2018, 19, 97.	1.4	18
57	Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 901-905.	2.2	39
58	Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer. <i>International Journal of Cancer</i> , 2017, 141, 191-199.	2.3	31
59	Metabolic biomarkers and gallstone disease – a population-based study. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1270-1277.	0.6	37
60	Association between routine laboratory tests and long-term mortality among acutely admitted older medical patients: a cohort study. <i>BMC Geriatrics</i> , 2017, 17, 62.	1.1	45
61	Soluble Urokinase Plasminogen Activator Receptor Is a Predictor of Incident Non-AIDS Comorbidity and All-Cause Mortality in Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Infectious Diseases</i> , 2017, 216, 819-823.	1.9	10
62	Routine blood tests are associated with short term mortality and can improve emergency department triage: a cohort study of >12,000 patients. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2017, 25, 115.	1.1	22
63	Introduction of a prognostic biomarker to strengthen risk stratification of acutely admitted patients: rationale and design of the TRIAGE III cluster randomized interventional trial. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2016, 24, 100.	1.1	8
64	Plasma suPAR is lowered by smoking cessation: a randomized controlled study. <i>European Journal of Clinical Investigation</i> , 2016, 46, 305-311.	1.7	40
65	Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1440-1442.	1.2	8
66	Low-dose growth hormone therapy reduces inflammation in HIV-infected patients: a randomized placebo-controlled study. <i>Infectious Diseases</i> , 2016, 48, 829-837.	1.4	7
67	Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. <i>Emergency Medicine Journal</i> , 2016, 33, 769-775.	0.4	90
68	suPAR level is associated with myocardial impairment assessed with advanced echocardiography in patients with type 1 diabetes with normal ejection fraction and without known heart disease or end-stage renal disease. <i>European Journal of Endocrinology</i> , 2016, 174, 745-753.	1.9	21
69	SuPAR Predicts Cardiovascular Events and Mortality in Patients With Asymptomatic Aortic Stenosis. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1462-1469.	0.8	11
70	Plasma Soluble CD163 Level Independently Predicts All-Cause Mortality in HIV-1-Infected Individuals. <i>Journal of Infectious Diseases</i> , 2016, 214, 1198-1204.	1.9	109
71	Weight loss is superior to exercise in improving the atherogenic lipid profile in a sedentary, overweight population with stable coronary artery disease: A randomized trial. <i>Atherosclerosis</i> , 2016, 246, 221-228.	0.4	28
72	Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years. <i>Hypertension Research</i> , 2015, 38, 439-444.	1.5	10

#	ARTICLE	IF	CITATIONS
73	Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls. <i>Immunity and Ageing</i> , 2015, 12, 9.	1.8	19
74	The formation and design of the TRIAGE study - baseline data on 6005 consecutive patients admitted to hospital from the emergency department. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2015, 23, 106.	1.1	21
75	Letters to the Editor: Genetic polymorphism and soluble urokinase plasminogen activator receptor regulation. <i>FASEB Journal</i> , 2015, 29, 4757-4758.	0.2	0
76	suPAR: The unspecific marker for disease presence, severity and prognosis. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, S33-S34.	1.1	43
77	Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population. <i>International Journal of Cardiology</i> , 2015, 184, 631-636.	0.8	38
78	Extracellular Matrix Biomarker, Fibulin-1 and Its Association with Soluble uPAR in a Bi-ethnic South African Population: The SAfrEIC Study. <i>Heart Lung and Circulation</i> , 2015, 24, 298-305.	0.2	5
79	suPAR: A New Biomarker for Cardiovascular Disease?. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1293-1302.	0.8	84
80	A Randomized Trial of an Early Measles Vaccine at 4½ Months of Age in Guinea-Bissau: Sex-Differential Immunological Effects. <i>PLoS ONE</i> , 2014, 9, e97536.	1.1	14
81	Extracellular Matrix Biomarker, Fibulin-1, Is Closely Related to NT-proBNP and Soluble Urokinase Plasminogen Activator Receptor in Patients with Aortic Valve Stenosis (The SEAS Study). <i>PLoS ONE</i> , 2014, 9, e101522.	1.1	13
82	Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects. <i>Atherosclerosis</i> , 2014, 237, 60-66.	0.4	41
83	Risk Factors Associated with Serum Levels of the Inflammatory Biomarker Soluble Urokinase Plasminogen Activator Receptor in a General Population. <i>Biomarker Insights</i> , 2014, 9, BML.S19876.	1.0	64
84	Development of a One-Step Probe Based Molecular Assay for Rapid Immunodiagnosis of Infection with <i>M. tuberculosis</i> Using Dried Blood Spots. <i>PLoS ONE</i> , 2014, 9, e105628.	1.1	18
85	Soluble Urokinase Plasminogen Activator Receptor as a Marker for Use of Antidepressants. <i>PLoS ONE</i> , 2014, 9, e110555.	1.1	35
86	CRP and suPAR are differently related to anthropometry and subclinical organ damage. <i>International Journal of Cardiology</i> , 2013, 167, 781-785.	0.8	99
87	Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. <i>International Journal of Cardiology</i> , 2013, 167, 2904-2911.	0.8	121
88	Soluble urokinase plasminogen activator receptor, C-reactive protein and triglyceride are associated with heart rate variability in non-diabetic Danes. <i>European Journal of Clinical Investigation</i> , 2013, 43, 457-468.	1.7	10
89	Soluble Urokinase Plasminogen Activator Receptor for Risk Prediction in Patients Admitted with Acute Chest Pain. <i>Clinical Chemistry</i> , 2013, 59, 1621-1629.	1.5	57
90	NT-proBNP, C-Reactive Protein and Soluble uPAR in a Bi-Ethnic Male Population: The SAfrEIC Study. <i>PLoS ONE</i> , 2013, 8, e58506.	1.1	19

#	ARTICLE	IF	CITATIONS
91	Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study. <i>BMJ Open</i> , 2012, 2, e001587.	0.8	32
92	Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study. <i>Critical Care</i> , 2012, 16, R130.	2.5	95
93	Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-study. <i>Thrombosis Research</i> , 2012, 130, 273-277.	0.8	19
94	Usefulness of Soluble Urokinase Plasminogen Activator Receptor to Predict Repeat Myocardial Infarction and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention. <i>American Journal of Cardiology</i> , 2012, 110, 1756-1763.	0.7	67
95	suPAR: The Molecular Crystal Ball. <i>Disease Markers</i> , 2009, 27, 157-172.	0.6	657
96	Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. <i>Journal of Medical Virology</i> , 2008, 80, 209-216.	2.5	108
97	Development and Validation of a Multiplex Add-On Assay for Sepsis Biomarkers Using xMAP Technology. <i>Clinical Chemistry</i> , 2006, 52, 1284-1293.	1.5	121
98	Prevalence and Prognostic Significance of Infection with TT Virus in Patients Infected with Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2000, 181, 1796-1799.	1.9	93